William Hunt Stafford

Dr. William Hunt Stafford


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
MSMohammad Sabobeh
Mohammad Sabobeh
ESElizabeth Seewer
Elizabeth Seewer
WSWilliam Hunt Stafford
William Hunt Stafford
NCNicolas Chiriboga
Nicolas Chiriboga
TSThomas Spentzas
Thomas Spentzas
SGSaad Ghafoor
Saad Ghafoor
Background: Critically ill children requiring extracorporeal membrane oxygenation (ECMO) support are at high risk of immobility, deconditioning, and muscle loss. There is a lack of screening and diagnostic tools to quantify muscle loss in this population. Objective: This study aims to evaluate the use of bedside ultrasound as a practical and effective method for detecting muscle loss in this high-risk group. Materials and Methods: This is a secondary analysis of a prospective observational clinical study conducted between January 2024 and January 2025 that used ultrasound to describe muscle loss in critically ill children aged 2 to 18 years. Results: The primary study enrolled 35 patients, five of whom required ECMO support. All patients who required ECMO showed significant muscle loss (>10%) in the quadriceps femoris, as measured by muscle thickness and cross-sectional area, compared with baseline measurements obtained before ECMO cannulation. Conclusions: Point-of-care muscle ultrasound could be a reliable, cost-effective tool for assessing muscle loss in pediatric patients on ECMO.

14 February 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
WSWilliam Hunt Stafford
William Hunt Stafford
Jennifer Ann McArthurJennifer Ann McArthur
Jennifer Ann McArthur
SGSaad Ghafoor
Saad Ghafoor
As survival rates for children with cancer and immune disorders have improved, clinical focus has shifted toward managing serious treatment-related complications. Intestinal perforation remains life-threatening and is typically diagnosed by signs of peritonitis and inflammation. This report presents three high-risk pediatric patients who developed severe intestinal perforation without the usual clinical symptoms. Each patient was receiving high-dose corticosteroids and/or targeted biologic immunomodulators (ruxolitinib, anakinra, tocilizumab, eculizumab). Classic indicators such as fever, leukocytosis, hemodynamic instability, and abdominal pain were absent, despite surgical findings of fecal contamination and bowel necrosis. All three patients survived to hospital discharge. These cases demonstrate that potent immunomodulatory therapies can mask the physiological response to perforation. Relying solely on traditional clinical signs may delay diagnosis. In this population, subtle findings such as persistent gastrointestinal bleeding, feeding intolerance, or minor imaging abnormalities should prompt consideration of perforation. Early imaging and multidisciplinary review are essential for timely intervention and improved outcomes.